Aap Implantate Ag · XETR:AAQ1
Aap Implantate — FY2016 Earnings Presentation
13 slides from Aap Implantate's earnings presentation, Apr 3, 2017
Slide 1: Annual Financial Statement FY/2016 Conference Call
aap Implantate AG Annual Financial Statement FY/2016 Conference Call Bruke Seyoum Alemu, CEO Marek Hahn, CFO Berlin, April 3, 2017
Slide 2: Safe Harbor Statement
Safe Harbor Statement Our publication may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual
Slide 3: Implementation of Strategic Imperatives (1/3)
Implementation of Strategic Imperatives (1/3) Key results and progress in FY/2016 – Status 12/31/2016 Focus on trauma Transformation to pure trauma player completed through divestments of aap Biomaterials GmbH and remaining stake in aap Joints GmbH LOQTEQ® Comprehensive system with more than
Slide 4: Implementation of Strategic Imperatives (2/3)
Implementation of Strategic Imperatives (2/3) Key results and progress in FY/2016 – Status 12/31/2016 Sales and Earnings Sales at EUR 10.5 million (FY/2015: EUR 12.3 million) EBITDA at EUR -7.9 million (FY/2015: EUR -6.8 million) Recurring EBITDA at EUR -5.6 million (FY/2015: EUR -5.5 millio
Slide 5: Implementation of Strategic Imperatives (3/3)
Implementation of Strategic Imperatives (3/3) Progress in FY/2016 Products Customers Accelerating Value-based Innovation Enhancing Market Enhancing Market Access Access LOQTEQ®: Completion of LOQTEQ® portfolio with Established countries: Focus on DACH, Established countries: Focus on DACH, Wes
Slide 6: Financial Figures FY/2016 (1/3)
Financial Figures FY/2016 (1/3) (in EUR million, sales bridge in KEUR) Sales FY/2016 FY/2015 Change Trauma 8.9 10.8 -18% thereof North America and Europe 6.8 4.5 +50% thereof RoW 2.1 6.3 -67% Other 1.6 1.5 +12% Sales continued operation 10.5 12.3 -15% Sales discontinued operation 4.2* 15.7** -73% Gr
Slide 7: Financial Figures FY/2016 (2/3)
Financial Figures FY/2016 (2/3) (in EUR million) EBITDA FY/2016 FY/2015 Change EBITDA continued operation -7.9 -6.8 -16% One-time effects 2.3* 1.3** +77% Recurring EBITDA continued operation -5.6 -5.5 -1% EBITDA discontinued operation 23.9*** 4.9 > +100% Group EBITDA 16.0*** -1.9 > +100% *Includes e
Slide 8: Financial Figures FY/2016 (3/3)
Financial Figures FY/2016 (3/3) (EBITDA bridge FY/2015 to FY/2016 (IFRS 5) in KEUR) 8
Slide 9: Highlights FY/2016 (Balance Sheet)
Highlights FY/2016 (Balance Sheet) • Sale of aap Biomaterials GmbH / Deconsolidation 05/11/2016: Disposal of assets of EUR 14.7 million and debts of EUR 2.7 million Balance sheet changed significantly • Total assets 12/31/2016: EUR 63.9 million (12/31/2015: EUR 54.9 million) +16% Non-current a
Slide 10: Highlights FY/2016 (Cash Flow)
Highlights FY/2016 (Cash Flow) • FY/2015 Cash Flow includes full Biomaterials business almost no comparability to FY/2016 • Operating Cash Flow FY/2016: EUR -7.2 million (FY/2015: EUR -2.3 million) Net result of EUR 14.6 million in FY/2016 incl. deconsolidation profit of EUR 23.2 million Posit
Slide 11: Outlook FY/2017
Outlook FY/2017 FY/2017 – Sales: EUR 10.0 million – EUR 13.0 million (FY/2016: EUR 10.5 million) – EBITDA: EUR -6.5 million – EUR -4.5 million (FY/2016: EUR -7.9 million) Q1/2017 – Sales: EUR 1.8 million – EUR 2.8 million (Q1/2016: EUR 2.5 million) – EBITDA: EUR -2.3 million – EUR -1.7 million (Q1/2
Slide 12: Management Agenda 2017 and beyond
Management Agenda 2017 and beyond Implementation of strategic imperatives Products Customers Accelerating Value-based Innovation Enhancing Enhancing Market Market Access Access LOQTEQ®: Completion of LOQTEQ® portfolio with a focus Established Established countries: countries: Focus Focus on on
Slide 13: Many thanks for your attention!
Many thanks for your attention! Lorenzweg 5 • 12099 Berlin • Germany Fabian Franke Manager Investor Relations Tel.: +49 30 750 19 – 134 Fax: +49 30 750 19 – 290 E-Mail: ir@aap.de IR-app: 13